RhythmOne shares soar as it sees full-year underlying earnings surge 900%

The digital advertising group said growth was led primarily by on-platform programmatic revenue, which saw an increase of approximately 13% year-on-year

digital marketing
RhythmOne said full-year revenue jumped by 71% to US$255mln from US$149mln

RhythmOne PLC (LON:RTHM) shares jumped higher on Thursday as the digital advertising group flagged up a surge in full-year results driven by the massive scale provided by its unified programmatic platform, RhythmMax.

In a trading update for the year ended 31 March 2018, the AIM-listed firm said its underlying adjusted earnings (EBITDA) soared by 900% to US$14mln, up from US$1.4mln a year earlier, as revenue jumped by 71% to US$255mln from US$149mln. 

READ: RhythmOne names new financial chief

The group said the growth was primarily led by on-platform programmatic revenue, which saw an increase of approximately 13% year-on-year.

During the fourth quarter, the company completed its acquisition of YuMe Inc, gaining access to premium video and connected TV inventory, unique audience data, cross-screen targeting technology and established demand relationships.

RhythmOne expects net cash on hand to total approximately US$26mln as at 31 March 2018, including the impact of the US$26mln acquisition consideration for the YuMe transaction, down from US39.3mln a year earlier.

Ted Hastings, RhythmOne's CEO, commented: “We believe we are well positioned to deliver a further strong performance in financial year 2019 – fully in line with current consensus estimates in market – as we realise the full contribution of the YuMe acquisition.”

He added: “Further, we will maintain strong cost discipline, driving efficiency within the company with the aim of sustained profitability and value generation for shareholders,” Hastings concluded.

In mid morning trading, RhythmOne shares were 18% higher at 210p.

Quick facts: RhythmOne

Price: - -

Market: AIM
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

1 day, 9 hours ago

2 min read